CRYZP1

Across TCGA pan-cancer cohorts, CRYZP1 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated CRYZP1 data layer.

The strongest signal is observed in brain lower grade glioma (LGG), where higher CRYZP1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRYZP1 expression acts as an unfavorable survival marker, although some lineages such as LAML and UCS show a favorable association.

LGG, KICH, and CESC are the cancer types where CRYZP1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.663	0.807	<.001	51	view →
KICH	DFS	Median	II,III,IV	0.574	0.916	.005	49	view →
CESC	DFS	Median	All	0.671	0.813	.003	36	view →
LAML	DFS	Tertile	All	0.552	0.353	.006	32	view →
UCS	DFS	Tertile	IV	0.956	0.422	.024	24	view →
KIRC	DFS	Median	IV	0.220	0.478	.003	19	view →
READ	OS	Quartile	All	0.945	0.355	.006	12	view →
ACC	OS	Tertile	IV	0.901	0.403	.006	12	view →
CHOL	DFS	Median	III,IV	0.127	0.647	.006	9	view →
UVM	DFS	Quartile	III,IV	0.252	0.797	.008	9	view →
BRCA	DFS	Median	III,IV	0.842	0.743	.018	9	view →
THCA	OS	Quartile	All	0.981	1.000	.011	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

CRYZP1–LGG (DFS)

Open the LGG breakdown →